<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04067947</url>
  </required_header>
  <id_info>
    <org_study_id>XG005-02</org_study_id>
    <nct_id>NCT04067947</nct_id>
  </id_info>
  <brief_title>Phase 1 Pharmacokinetics, Safety, and Tolerability Study</brief_title>
  <official_title>A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Ascending Single and Multiple Oral Dose Study of the Pharmacokinetics, Safety, and Tolerability of XG005 in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xgene Pharmaceutical Pty Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Xgene Pharmaceutical Pty Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Ascending Single and Multiple Oral
      Dose Study of the Pharmacokinetics, Safety, and Tolerability of XG005 in Healthy Volunteers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, double-blind, placebo-controlled study which will investigate the PK,
      safety, and tolerability of four ascending single and multiple oral doses of XG005 in healthy
      subjects. The trial consists of two parts: a single ascending dose (SAD) PK evaluation (Part
      1) and a multiple ascending dose (MAD) PK evaluation (Part 2). Approximately 32 Subjects will
      be enrolled sequentially into a total of 4 ascending dose levels in each part.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 8, 2019</start_date>
  <completion_date type="Actual">February 10, 2020</completion_date>
  <primary_completion_date type="Actual">December 3, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>The Investigator or designee, study coordinator(s), subjects, the Sponsor study team and its representatives, will be blinded to the treatment assignment.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Event related to XG005</measure>
    <time_frame>Day 1 to 7 days after last dose</time_frame>
    <description>Adverse Event reported as mild, moderate, severe on physical exam, ECG and laboratory results</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">64</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>XG005</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>XG005 in 4 dose levels</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo in all cohort</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>XG005</intervention_name>
    <description>XG005 Tablet</description>
    <arm_group_label>XG005</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <description>Placebo Tablet</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy males or females between 18 and 55 years of age

          2. BMI 18.0 to 30.0 kg/m2

          3. Non-pregnant, non-breastfeeding female subjects

        Exclusion Criteria:

          1. Unstable or severe illness

          2. History of, or current treatment for, GI disease

          3. Clinically significant history of medical condition associated with GI events

          4. History of or current glucose intolerance or gestational diabetes

          5. Lifetime history of suicidal behavior

          6. Creatinine clearance &lt; 90 mL/min

          7. Any elevation of liver function tests

          8. Creatine kinase (CK) value of greater than 1.5 times the upper limit

          9. Leucocytes or lymphocytes less than 1.5 times the lower limit of normal

         10. Positive Hepatitis B surface antigen, HCV, or HIV
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Feng Xu, PHD</last_name>
    <role>Study Chair</role>
    <affiliation>Xgene Pharmaceutical Pty Ltd</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Linear Clinical Research Ltd</name>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>August 13, 2019</study_first_submitted>
  <study_first_submitted_qc>August 21, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 28, 2019</study_first_posted>
  <last_update_submitted>February 19, 2020</last_update_submitted>
  <last_update_submitted_qc>February 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

